Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04519073 |
Recruitment Status :
Completed
First Posted : August 19, 2020
Last Update Posted : March 7, 2022
|
Sponsor:
Virometix
Collaborators:
Center of Vaccinology, Ghent, Belgium (CEVAC)
Expert Clinical Services Organization, Brussels, Belgium (ECSOR)
Information provided by (Responsible Party):
Virometix
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | March 2, 2022 |
Actual Study Completion Date : | March 2, 2022 |